Status

Current conditions ICD-9-CM:
2003
225.0 BENIGN NEOPLASM OF BRAIN
345.90 UNSPECIFIED EPILEPSY WITHOUT MENTION OF INTRACTABLE EPILEPSY
2010
225.0 BENIGN NEOPLASM OF BRAIN
345.90 UNSPECIFIED EPILEPSY WITHOUT MENTION OF INTRACTABLE EPILEPSY
2012
225.0 BENIGN NEOPLASM OF BRAIN
345.90 UNSPECIFIED EPILEPSY WITHOUT MENTION OF INTRACTABLE EPILEPSY
375.15 TEAR FILM INSUFFICIENCY,UNSPECIFIED
367.89 OTHER DISORDERS OF REFRACTION AND ACCOMMODATION
377.61 ASSOCIATED WITH NEOPLASMS
729.1 MYALGIA AND MYOSITIS, UNSPECIFIED
719.39 PALINDROMIC RHEUMATISM,MULTIPLE SITES
680.0 CARBUNCLE AND FURUNCLE, FACE
378.41 ESOPHORIA
311 DEPRESSIVE DISORDER, NOT ELSEWHERE CLASSIFIED
523.8 OTHER PERIODONTAL DISEASES(PERIODONTAL POCKET,GINGIVAL POLYP)
681.02 ONYCHIA AND PARONYCHIA OF FINGER
2013
225.0 BENIGN NEOPLASM OF BRAIN
345.90 UNSPECIFIED EPILEPSY WITHOUT MENTION OF INTRACTABLE EPILEPSY
704.8 OTHER DISEASES OF HAIR AND HAIR FOLLICLES
706.1 OTHER ACNE
444.22 ARTERIAL EMBOLISM AND THROMBOSIS OF LOWER EXTREMITY
375.15 TEAR FILM INSUFFICIENCY,UNSPECIFIED
367.89 OTHER DISORDERS OF REFRACTION AND ACCOMMODATION
377.61 ASSOCIATED WITH NEOPLASMS
378.41 ESOPHORIA
728.85 (728.850) SPASM OF MUSCLE
353.4 LUMBOSACRAL ROOT LESIONS,NOT ELSEWHERE CLASSIFIED
780.52 (780.520) OTHER INSOMNIA
788.43 NOCTURIA
2014
225.0 BENIGN NEOPLASM OF BRAIN
345.90 UNSPECIFIED EPILEPSY WITHOUT MENTION OF INTRACTABLE EPILEPSY
374.05 TRICHIASIS WITHOUT ENTROPION
372.72 CONJUNCTIVAL HEMORRHAGE
375.15 TEAR FILM INSUFFICIENCY,UNSPECIFIED
367.89 OTHER DISORDERS OF REFRACTION AND ACCOMMODATION
377.61 ASSOCIATED WITH NEOPLASMS
378.41 ESOPHORIA
2015
225.0 BENIGN NEOPLASM OF BRAIN
345.90 UNSPECIFIED EPILEPSY WITHOUT MENTION OF INTRACTABLE EPILEPSY
705.83 HIDRADENITIS
698.8 OTHER PRURITIC CONDITIONS
686.9 UNSPECIFIED LOCAL INFECTIONS OF SKIN AND SUBCUTANEOUS TISSUE
686.09 OTHER PYODERMA
272.0 PURE HYPERCHOLESTEROLAEMIA (FAMILIAL HYPERCHOLESTESTEROLEMIA)
729.1 MYALGIA AND MYOSITIS, UNSPECIFIED
719.39 PALINDROMIC RHEUMATISM,MULTIPLE SITES
377.61 ASSOCIATED WITH NEOPLASMS
311 DEPRESSIVE DISORDER, NOT ELSEWHERE CLASSIFIED
307.48 REPETITIVE INTRUSIONS OF SLEEP
705.81 DYSHIDROSIS
372.72 CONJUNCTIVAL HEMORRHAGE
680.2 CARBUNCLE AND FURUNCLE, TRUNK
523.3 ACUTE PERIODONTITIS(ACUTE PERICORONITIS)
Current conditions ICD-10-CM:
2016

E780 Pure hypercholesterolemia
G40.909 Epilepsy, unspecified, not intractable, without status epilepticus
L301 Dyshidrosis [pompholyx]
F32.9 Major depressive disorder, single episode, unspecified
D33.2 Benign neoplasm of brain, unspecified
H04.123 Dry eye syndrome of bilateral lacrimal glands
H47.529 Disorders of visual pathways in (due to) neoplasm, unspecified side
H02.052 Trichiasis without entropian right lower eyelid
H11.31 Conjunctival hemorrhage, right eye
H52.6 Other disorders of refraction
H50.51 Esophoria
H02.055 Trichiasis without entropian left lower eyelid
H47.099 Other disorders of optic nerve, not elsewhere classified, unspecified eye
F51.8 Other sleep disorders not due to a substance or known physiological condition
G40.901 Epilepsy, unspecified, not intractable, with status epilepticus
L0881 Pyoderma vegetans
B009 Herpesviral infection, unspecified
J069 Acute upper respiratory infection, unspecified
M79.1 Myalgia
M12.39 Palindromic rheumatism, multiple sites

Current treatment centers:
GP/ The department of Neurosurgical emergency & Critical Care of Chang Gung Memorial Hospital Linkou Branch/ TCM oncology of China Medical University Hospital Cancer Center/ and Taichung Hospital, Ministry of Health and Welfare

Contents of reference sources:
MIMS- Search drug information/ interaction/ images & medical diagnosis.
Complementary and Alternative Healing University- Dictionary of Chinese Herbs. http://alternativehealing.org
Database 醫砭‧沈藥子 http://yibian.hopto.org
Traditional Chinese Medicine (TCM) Wiki http://www.tcmwiki.com/

Monday, April 4, 2011

DILANTIN

DILANTIN (Dī lan' tĭn)
(Phenytoin and Phenytoin sodium)
Oral Suspension, Tablets, Extended Oral Capsules
Read this Medication Guide before you start taking DILANTIN and each time you get a
refill. There may be new information.  This information does not take the place of
talking to your healthcare provider about your medical condition or treatment.  If you
have any questions about DILANTIN, ask your healthcare provider or pharmacist.  
What is the most important information I should know about DILANTIN?
Do not stop taking DILANTIN without first talking to your healthcare provider.  
Stopping DILANTIN suddenly can cause serious problems.  
DILANTIN can cause serious side effects including:
1.  Like other antiepileptic drugs, DILANTIN may cause suicidal thoughts or
actions in a very small number of people, about 1 in 500.
Call a healthcare provider right away if you have any of these symptoms,
especially if they are new, worse, or worry you:
 thoughts about suicide or dying
• attempts to commit suicide
• new or worse depression
• new or worse anxiety
• feeling agitated or restless
• panic attacks
• trouble sleeping (insomnia)
• new or worse irritability
• acting aggressive, being angry, or violent
• acting on dangerous impulses
• an extreme increase activity and talking (mania)
• other unusual changes in behavior or mood
How can I watch for early symptoms of suicidal thoughts and actions?
 Pay attention to any changes, especially sudden changes, in mood, behaviors,
thoughts, or feelings.
• Keep all follow-up visits with your healthcare provider as scheduled.
Call your healthcare provider between visits as needed, especially if you are worried
about symptoms.  
Reference ID: 2888819  10  

Do not stop taking DILANTIN without first talking to a healthcare provider.
 Stopping DILANTIN suddenly can cause serious problems.  Stopping a seizure
medicine suddenly in a patient who has epilepsy can cause seizures that will not
stop (status epilepticus).
Suicidal thoughts or actions can be caused by things other than medicines.  If you have
suicidal thoughts or actions, your healthcare provider may check for other causes.
2.  Dilantin may harm your unborn baby.
 If you take DILANTIN during pregnancy, your baby is at risk for serious birth
defects.
• Birth defects may occur even in children born to women who are not taking
any medicines and do not have other risk factors  
• If you take DILANTIN during pregnancy, your baby is also at risk for
bleeding problems right after birth.  Your healthcare provider may give you
and your baby medicine to prevent this.  
• All women of child-bearing age should talk to their healthcare provider about
using other possible treatments instead of DILANTIN.  If the decision is made
to use DILANTIN, you should use effective birth control (contraception)
unless you are planning to become pregnant.
• Tell your healthcare provider right away if you become pregnant while taking
DILANTIN. You and your healthcare provider should decide if you will take
DILANTIN while you are pregnant.
• Pregnancy Registry: If you become pregnant while taking DILANTIN, talk to
your healthcare provider about registering with the North American
Antiepileptic Drug Pregnancy Registry. You can enroll in this registry by
calling 1-888-233-2334. The purpose of this registry is to collect information
about the safety of antiepileptic drugs during pregnancy.
3. Swollen glands (lymph nodes)  
4.  Allergic reactions or serious problems which may affect organs and other
parts of your body like the liver or blood cells.  You may or may not have a rash
with these types of reactions. Symptoms include:
 swelling of your face, eyes, lips, or tongue
• trouble swallowing or breathing
• a skin rash
• hives
• fever, swollen glands, or sore throat that do not go away or come and go
• painful sores in the mouth or around your eyes
• yellowing of your skin or eyes
Reference ID: 2888819  11 •  unusual bruising or bleeding
• severe fatigue or weakness
• severe muscle pain
• frequent infections or an infection that does not go away
Call your healthcare provider right away if you have any of the symptoms listed
above.
What is DILANTIN?
DILANTIN is a prescription medicine used to treat tonic-clonic (grand mal), complex
partial (psychomotor or temporal lobe) seizures, and to prevent and treat seizures that
happen during or after brain surgery.
Who should not take DILANTIN?
Do not take DILANTIN if you:
 are allergic to phenytoin or any of the ingredients in DILANTIN. See the end
of this leaflet for a complete list of ingredients in DILANTIN.
• have had an allergic reaction to CEREBYX (fosphenytoin), PEGANONE
(ethotoin), or MESANTOIN (mephenytoin).
What should I tell my healthcare provider before taking DILANTIN?
Before you take DILANTIN, tell your healthcare provider if you:
• Have or had liver disease
• Have or had porphyria
• Have or had diabetes
• Have or have had depression, mood problems, or suicidal thoughts or behavior
• Are pregnant or plan to become pregnant.
o  If you become pregnant while taking DILANTIN, the level of
DILANTIN in your blood may decrease, causing your seizures to
become worse.  Your healthcare provider may change your dose of
DILANTIN.
• Are breast feeding or plan to breastfeed. DILANTIN can pass into breast milk.
You and your healthcare provider should decide if you will take DILANTIN or
breastfeed. You should not do both.
Tell your healthcare provider about all the medicines you take, including
prescription and non-prescription medicines, vitamins, and herbal supplements.  
Taking DILANTIN with certain other medicines can cause side effects or affect how
well they work. Do not start or stop other medicines without talking to your
healthcare provider.
Reference ID: 2888819  12 Know the medicines you take.  Keep a list of them and show it to your healthcare
provider and pharmacist when you get a new medicine.  
How should I take DILANTIN?
 Take DILANTIN exactly as prescribed. Your healthcare provider will tell you
how much DILANTIN to take.
• Your healthcare provider may change your dose.  Do not change your dose of
DILANTIN without talking to your healthcare provider.
• DILANTIN can cause overgrowth of your gums.  Brushing and flossing your
teeth and seeing a dentist regularly while taking DILANTIN can help prevent
this.
• If you take too much DILANTIN, call your healthcare provider or local Poison
Control Center right away.
• Do not stop taking DILANTIN without first talking to your healthcare provider.
Stopping DILANTIN suddenly can cause serious problems.  
What should I avoid while taking DILANTIN?
Do not drink alcohol while you take DILANTIN without first talking to your healthcare
provider. Drinking alcohol while taking DILANTIN may change your blood levels of
DILANTIN which can cause serious problems.
Do not drive, operate heavy machinery, or do other dangerous activities until you know
how DILANTIN affects you. DILANTIN can slow your thinking and motor skills.
What are the possible side effects of DILANTIN?
See “What is the most important information I should know about DILANTIN?”
DILANTIN may cause other serious side effects including:
• Softening of your bones (osteomalacia).  This can cause broken bones.
Call your healthcare provider right away, if you have any of the symptoms listed
above.
The most common side effects of DILANTIN include:
 problems with walking and coordination
• slurred speech
• confusion
• dizziness
• trouble sleeping
• nervousness
• tremor
• headache
• nausea
Reference ID: 2888819  13 •  vomiting
• constipation
• rash
These are not all the possible side effects of DILANTIN. For more information, ask your
healthcare provider or pharmacist.  
Tell your healthcare provider if you have any side effect that bothers you or that does not
go away.
Call your doctor for medical advice about side effects.  You may report side
effects to FDA at 1-800-FDA-1088.
How should I store DILANTIN?
 Store DILANTIN-125 Suspension at room temperature between 68°F to 77°F
(20°C to 25°C). Protect from light.  Do not freeze.
• Store DILANTIN INFATABS at room temperature between 59°F to 86°F (15°C
to 30°C).
• Store DILANTIN Capsules at room temperature between 68°F to 77°F (20°C to
25°C) in tight, light-resistant containers. Protect from moisture.
Keep DILANTIN and all medicines out of the reach of children.
General information about DILANTIN
Medicines are sometimes prescribed for purposes other than those listed in a Medication
Guide. Do not use DILANTIN for a condition for which it was not prescribed. Do not
give DILANTIN to other people, even if they have the same symptoms that you have.  It
may harm them.
This Medication Guide summarizes the most important information about DILANTIN.  If
you would like more information, talk with your healthcare provider.  You can ask your
healthcare provider or pharmacist for information about DILANTIN that was written for
healthcare professionals.
For more information about DILANTIN, visit http://www.pfizer.com or call
1-800-438-1985.
What are the ingredients in DILANTIN?
Oral Suspension
Active ingredient: phenytoin
Inactive ingredients: USP; alcohol, USP (maximum content not greater than 0.6 percent);
banana flavor; carboxymethylcellulose sodium, USP; citric acid, anhydrous, USP;
glycerin, USP; magnesium aluminum silicate, NF; orange oil concentrate; polysorbate
40, NF; purified water, USP; sodium benzoate, NF; sucrose, NF; vanillin, NF; and FD&C
yellow No. 6.
Reference ID: 2888819  14  
Tablet


Each tablet is a yellow triangular scored chewable tablet.
Active ingredient: 50 mg phenytoin
Inactive ingredients: D & C yellow No. 10, A1 lake, FD&C yellow No. 6, flavor,
saccharin sodium, sucrose, talc, and other ingredients.  
Extended Oral Capsule
Dilantin 100mg: Each capsule contains a white powder.  The medium orange cap has
“PD” imprinted in black ink and the white, opaque body has “DILANTIN” over
“100 mg” printed in black ink.
Active ingredient: 100 mg phenytoin sodium
Inactive ingredients: lactose monohydrate, confectioner’s sugar, talc, and magnesium
stearate. The capsule body contains titanium dioxide and gelatin.  The capsule cap
contains FD&C red No. 28, FD&C yellow No. 6, and gelatin.
Dilantin 30mg: Each capsule contains a white powder.  The small pale pink opaque cap
has “PD” imprinted in black ink and the white, opaque body has “Dilantin 30 mg”
printed in black ink.
Active ingredient: 30 mg phenytoin sodium


Inactive ingredients: lactose monohydrate, confectioner’s sugar, talc, and magnesium


stearate. The capsule shell cap and body contain Titanium Dioxide (cap and body);
gelatin (cap and body); D&C yellow No. 10 (cap); FD&C red No. 3 (cap).
This Medication Guide has been approved by the U.S. Food and Drug Administration.  
LAB-0398-1.0
Revised November 2010
Reference ID: 2888819  15

No comments:

Post a Comment